Pfizer (PFE)

Merck's Capvaxive vaccine showed strong immune responses and a comparable safety profile to PPSV23 in high-risk children during the Phase 3 STRIDE-13 trial.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs.

The global economy is once again grappling with the disquieting prospect of stagflation, a rare and challenging economic phenomenon defined by the simultaneous occurrence of slow economic growth, high unemployment, and persistent inflation. This peculiar confluence, which defies traditional economic models, is sending ripples of concern through financial markets and

Top health officials under Kennedy are pushing for more transparency on Covid vaccine risks, focusing on pregnant women and child deaths, amid disputes with GOP lawmakers and industry leaders.

With a 6.2% yield, this high yielder is focused on supporting the innovation that drives the healthcare industry forward.

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 4.8% in the afternoon session after competitors Pfizer and BioNTech announced positive topline results for their updated 2025-2026 COVID-19 vaccine formula. The data from Pfizer and BioNTech showed their vaccine produced a robust immune response, signaling continued strong competition in the COVID-19 vaccine market. 

Pfizer and BioNTech's LP.8.1 COVID-19 vaccine boosts antibodies 4-fold in high-risk adults, with no new safety concerns reported.

The company is working on a treatment for a form of epilepsy that tends to be difficult to control.

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

Summit Therapeutics stock crashed Monday after the company's drug failed to meet the bar for overall survival in lung cancer.

The market may have been too quick to dismiss this biotech's pipeline prospects after a recent trial result.

Pfizer's stock is down nearly 60% from its post-pandemic peak, opening up an opportunity for the right long-term investors.

The company might be close to commercializing its most advanced pipeline program.

It's unprecedented times for the Covid vaccine market, experts say. And Pfizer and Moderna remain under significant pressure.

Viking aims to enter the billion-dollar weight loss drug market.

Secretary for Health and Human Services, Robert F. Kennedy Jr., faced bipartisan backlash during a combative Senate hearing on Thursday, as both Republicans and Democrats criticized his controversial vaccine policies and the abrupt firing of Centers for Disease Control and Prevention Director Susan Monarez.

Explore the S&P500 index on Thursday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest.

These stocks are cheap in more ways than one.

Pfizer has a lofty 6.9% dividend yield, but is it the only or best choice for investors interested in the pharma space?

California, Oregon and Washington form regional vaccine alliance to counter federal guidance under Robert F. Kennedy Jr. as Florida eliminates state mandates.